Friday, 16 October 2026European Markets
ExploreSearch
ViaNews EU
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· May 25, 2026

Stellora.AI Advances Quantum Flow to Support Healthcare, Drug Discovery, and Disease Research

View original at globenewswire.com
Stellora.AI Advances Quantum Flow to Support Healthcare, Drug Discovery, and Disease Research Prague, Czechia, May 25, 2026 (GLOBE NEWSWIRE) -- Stellora.AI, a deep-tech artificial intelligence startup developing advanced agentic AI and quantum workflow technology, today announced the continued advancement of Stellora.A…
Opening lines of the source · GlobeNewswire · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Stellora.AI is opening demo access because it wants serious partners to experience where the technology is going and how it can support meaningful scientific progress.

    60% confidence

  • Quantum Flow is not intended to replace researchers, doctors, or pharmaceutical laboratories, but is being developed as a powerful workflow assistant for scientific teams.

    60% confidence

  • Quantum Flow is designed to generate functional quantum circuits and quantum code tailored to specific research goals, working with scientific studies, quantum theories, target machine SDK documentation, and target quantum machine requirements.

    60% confidence

  • With Quantum Flow, Stellora.AI is building a bridge between validated research, quantum SDKs, and functional quantum circuits so researchers can move faster from idea to experimentation.

    60% confidence

  • Stellora.AI sees Quantum Flow as applicable for biomedical discovery, computational chemistry, precision medicine, and disease research where complex modeling and simulation are essential.

    60% confidence

  • Every improvement in Quantum Flow brings Stellora.AI closer to a future where AI can help scientists generate, test, and refine quantum workflows for healthcare, drug discovery, and disease research, with the goal of empowering researchers rather than replacing them.

    60% confidence

  • Stellora.AI was never created to be just another AI tool. Our mission is to help humanity by making advanced, trusted intelligence available for the most important scientific challenges.

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com